I.The Pharmaceutical Industry’s Approach to Stem Cells For decades, people with Parkinson’s have been waiting for solutions that go beyond current treatments, which alleviate symptoms without stopping the disease’s progression. It is well known that these symptomatic treatments lose effectiveness…
In this new edition of our newsletter, we invite you to meet Guy. Throughout his journey, Guy has discovered in AtremoPlus a valuable ally that helps him preserve his independence and maintain the quality of life he holds so dear.…
In this new Portrait, we are pleased to give the word to Birgit Lange, who was diagnosed with Parkinson’s disease at the young age of 37. As the regional delegate of the dPV (German Parkinson’s Association), Birgit channels her fight…
In our latest newsletter, we discussed our commitment to understanding the mechanisms of action and measuring key parameters and biomarkers. This approach allows us to quantify the concrete impact on motor and cognitive performance, with observable effects shortly after initial intake. In…
Did you know that L-dopa was first discovered by Markus Guggenheim in 1913, and that he isolated it from the Vicia faba plant? Furthermore, did you know that numerous scientific studies from expert teams worldwide have demonstrated that the Vicia…
In this new newsletter, we will delve deeper into our quest to make things measurable and thus quantify the improvements following the use of AtremoPlus. “Advances in medicine often result from the ability to accurately measure biological phenomena (…). Biomarkers…
In our previous newsletters, we addressed the improvement of energy for AtremoPlus users. In this new edition, we will focus on a related theme: chronic fatigue and daytime sleepiness. Feeling constantly tired and lacking energy, even to stay awake during the…
In this new edition of our newsletter, we will delve a little deeper into this fascinating, somewhat intangible phenomenon, yet so important: Energy. Without energy, life can become dull, laborious, and exhausting, and we know that in Parkinson’s disease, which…